These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22451133)

  • 1. [Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain].
    Sanz-Granda A; Garcia-Jurado L; Polanco-Sanchez C
    Rev Neurol; 2012 Apr; 54(7):446-7; author reply 447-8. PubMed ID: 22451133
    [No Abstract]   [Full Text] [Related]  

  • 2. [Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain].
    Sánchez-De la Rosa R; Sabater E; Casado MA
    Rev Neurol; 2011 Aug; 53(3):129-38. PubMed ID: 21748710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis.
    Crespo C; Izquierdo G; García-Ruiz A; Granell M; Brosa M
    Neurologia; 2014 May; 29(4):210-7. PubMed ID: 24161412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
    Johnson KP; Due DL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective.
    Nuijten M; Mittendorf T
    Clin Ther; 2010 Apr; 32(4):717-28. PubMed ID: 20435242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain].
    Rubio-Terrés C; Domínguez-Gil Hurlé A
    Rev Neurol; 2005 Jun 16-30; 40(12):705-10. PubMed ID: 15973634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
    Dorman E; Kansal AR; Sarda S
    J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
    Chevalier J; Chamoux C; Hammès F; Chicoye A
    PLoS One; 2016; 11(3):e0150703. PubMed ID: 26987055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.
    Montgomery SM; Maruszczak MJ; Slater D; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 May; 20(5):474-482. PubMed ID: 28008769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W; Kansal A; Vicente C; Deniz B; Sarda S
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacy benefit forecast for a new interferon Beta-1a for the treatment of multiple sclerosis: development of a first-line decision tool for pharmacy-budget planning using administrative claims data.
    Meyer CM; Phipps R; Cooper D; Wright A
    J Manag Care Pharm; 2003; 9(2):168-74. PubMed ID: 14613346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
    Paolicelli D; Iannazzo S; Santoni L; Iaffaldano A; Di Lecce V; Manni A; Lavolpe V; Tortorella C; D'Onghia M; Direnzo V; Puma E; Trojano M
    PLoS One; 2016; 11(7):e0159214. PubMed ID: 27390865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
    J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.
    Najafi B; Ghaderi H; Jafari M; Najafi S; Ahmad Kiadaliri A
    Glob J Health Sci; 2014 Oct; 7(2):139-47. PubMed ID: 25716386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.